2022.03.30
On March 30, 2022, Shanghai Rendu Biotechnology Co., Ltd. (Rendu Biotechnology) was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange with the stock code 688193. The issue price was RMB 72.65 per share, raising a total of RMB 726.5 million.
Rendu Biotechnology was founded in 2007. It is a domestic high-tech enterprise focused on RNA molecular diagnosis technology and products. Its main business is the R & D, production and sales of molecular diagnosis reagents and equipment integrated products based on its technology platform. Rendu Biotechnology provides solutions for the accurate diagnosis, effective prevention, and personalized diagnosis and treatment of pathogens in the fields of reproduction, respiration, digestion, blood, food, and environmental safety. Rendu Biotechnology is committed to developing and promoting RNA molecular diagnostic products based on simultaneous amplification and testing (SAT technology). It has a complete set of independent intellectual property rights and core technologies ranging from diagnostic reagents to the R&D and production of fully automatic supporting instruments. The company has successfully established its SAT technology platform; 42 relevant patents have been licensed, and 20 products have obtained NMPA registration certificates and are now on the market. Compared with DNA molecular diagnosis (PCR), SAT has the advantage of high sensitivity and specificity, low cross-contamination and easy to realize automatic high-throughput detection. Molecular diagnostics based on SAT technology can be used in many areas including clinical detection, blood screening, food safety, infectious diseases, emergency prevention and rapid response.
JunHe acted as the legal counsel of China International Capital Corporation Limited (CICC), which was the sponsor and the lead underwriter of this project. JunHe’s team provided comprehensive legal services for the A-share listing of Rendu Biotechnology during the whole process. They assisted the sponsor (lead underwriter) in carrying out various due diligence work, assisted in drafting and revising the prospectus and the application and issuance documents related to the listing, and assisted in responding to feedback from the Shanghai Stock Exchange and China Securities Regulatory Commission. JunHe’s consistently effective, rigorous, and steady work style and its meticulous and professional service attitude won the unanimous affirmation and high recognition of the client and the other intermediaries.
This project was led by Partners Mr. SHAO, Chunyang and Mr. NIU, Yuandong.
